OVERVIEW

Hypoparathyroidism: therapeutic updates and optimizing treatment is organized by ScientiaCME.

Release Date: Jun 06, 2018
Expiration Date: Jun 06, 2020

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Pharmacists:
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-18-022-H01-P. ACPE Accreditation effective 06/16/18, expires 06/16/2020. This is a Knowledge (K)-type activity.

Description:
Hypoparathyroidism is a rare disorder characterized by decreased function of parathyroid glands resulting in low levels of parathyroid hormone (PTH). There may be a variety of causes that include autoimmune disease, congenital defects, unintended removal during thyroidectomy, or as a result of damage due to radiation therapy. In a normal functioning parathyroid gland, PTH is secreted in response to low serum-ionized calcium. Patients with hypoparathyroidism experience abnormal mineral homeostasis affecting bone, kidney, and the gastrointestinal tract. Pathogenesis of the condition includes reduced osteoclast-mediated bone resorption, reduced calcium reabsorption in the distal convoluted tubules of the kidneys, and increased phosphorus reabsorption from the proximal convoluted tubules, causing hyperphosphatemia. In severe, untreated cases, hypocalcemia can result in abnormal skeletal formation, cognitive impairment, bronchospasms, laryngospasms, neuromuscular irritability and cardiac issues.

Objectives:
By the end of the session the participant will be able to:
• Describe the pathophysiology and underlying etiologies of hypoparathyroidism and apply these to patient cases.
• Describe the clinical manifestations of hypoparathyroidism and discuss how they may have relevance to treatment targets.
• Identify available therapeutic options for hypoparathyroidism and incorporate these in the development of treatment plans in patient cases.
• Define patient-specific goals related to the management of hypoparathyroidism.